{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

An observational survey to evaluate management pattern of Connective tissue disorder associated ILD and to understand the role of anti-fibrotics
Doctor's details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

Questionnaire

  1. How many patients of Interstitial lung disease (ILD) do you see in a month? *

  2. How do you confirm a diagnosis of ILD in the majority of your patients? *

    3. *Biopsy and BAL: When indicated
  3. What percentage of your ILD patients have BAL performed? *

  4. What percentage of your ILD patients have biopsies performed? *

  5. If you perform biopsy, for an idiopathic interstitial pneumonia which of the following methods do you generally prefer?

    6. *Usually after MDD discussion, followed by discussion with patient
  6. What percentage of ILD patients have CTD-ILD? *

  7. Which is the most common CTD-ILD encountered in your clinical practice? *

  8. Which patients do you screen for ILD? *

  9. How many patients of systemic sclerosis associated ILD (Ssc ILD) do you see in a month? *

  10. How many patients of RA-ILD do you see in a month? *

  11. How many patients of Sjogren’s syndrome associated ILD do you see in a month? *

  12. How many patients of idiopathic inflammatory myopathies assocated ILD do you see in a month? *

  13. What is the percentage of patients which present with each symptom in Ssc-ILD? *
    14. Percentage of patients with each symptom
    %
    %
    %
    %
    %
    %
  14. What is the percentage of patients which present with each symptom inRA-ILD? *
    15. Percentage of patients with each symptom
    %
    %
    %
    %
    %
    %
  15. What is the percentage of patients which present with each symptom in Sjogren’s syndrome associated-ILD? *
    16. Percentage of patients with each symptom
    %
    %
    %
    %
    %
    %
  16. What is the percentage of patients which present with each symptom in IDIOPATHIC INFLAMMATORY MYOPATHIES -ILD? *
    17. Percentage of patients with each symptom
    %
    %
    %
    %
    %
    %
  17. How often ILD is the first presentation for patients with systemic sclerosis? *

  18. Are young, middle-aged women most affected with SSc-ILD in your clinical practice? *

  19. What are the clinical signs of Ssc-ILD in your clinical practice? *
  20. What are the clinical signs of RA-ILD in your clinical practice? *
  21. What are the clinical signs of idiopathic inflammatory myopathies -ILD in your clinical practice? *
  22. What are the clinical signs of Sjogren’s syndrome associated-ILD in your clinical practice? *
  23. What are the confirmatory diagnostic tests for Ssc-ILD done by you? *
  24. What are the common extrapulmonary manifestations of Ssc-ILD that you have observed in your practice? *
  25. What is the average time from onset of symptoms to a “reasonably secure” diagnosis in your patients with ILDs? *

    26. “Reasonably secure”: When you feel, you have a reasonable treatment plan in place.
  26. What percentage of your patients with non-IPF ILD develop a “progressive fibrosing” phenotype? *

    27. “Progressive fibrosing”: Progression of fibrosis on CT to be determined by the audience but the criteria for progression was given to them for reference.
  27. Which of the following would you perform on follow-up? (You may tick more than one alternative) *

  28. What are the treatment modalities that you use to treat the majority of your patients with the following types of ILD? (You may tick more than one alternative for each category). *
    29. Drugs/ILD type Antifibrotics NAC Steroids Immunosuppressant

  29. What percentage of the below immunosuppressants do you prescribe for your CTD-ILD patients? *
    30. Drugs/ILD type >50% 20–50% <20%

  30. What are your common reasons for preferring the above immunosuppressant for >50% of the time? *

  31. In your opinion, how would you rate mycophenolate mofetil over azathioprine in your patients with CTD-ILD in terms of (Please tick the most applicable one) *
    32. Efficacy Safety

  32. If there are safety concerns you encounter with azathioprine or mycophenolate mofetil, please specify.
  33. Do you prescribe antifibrotics in your patients with progressive CTD ILDs? *

  34. Are antifibrotics preferred when patients fail to tolerate immunosuppressive therapy? *

  35. Are antifibrotics preferred when patients fail to respond/improve with immunosuppressive therapy? *

  36. How much percentage of patients do not tolerate immunosuppressant therapy? *
    37. 0-5% 5-10 % 10-20% >20%

  37. How much percentage of patients who do not respond/improve with immunosuppressant therapy? *
    38. 0-5% 5-10 % 10-20% >20%

  38. Antifibrotics are which line of treatment? *
    39. 1st Line 2nd Line 3rd Line

  39. Is nintedanib preferred antifibrotic in all patients with CTD-ILD? *

  40. Nintedanib is the treatment of choice in which patient profile of SSc-ILD based on your clinical experience? *
  41. Which symptom of Ssc-ILD improves the most with Nintedanib as per your clinical expertise? *
  42. According to you, for how long therapy with Nintedanib should be given in patients with Ssc-ILD? *

  43. How commonly patients with Ssc-ILD are followed up? *

  44. Which are the diagnostic tests commonly done by you to Ssc-ILD patient during follow up? *
  45. According to you, for how long therapy with Nintedanib should be given in patients with RA-ILD? *

  46. According to you, for how long therapy with Nintedanib should be given in patients with idiopathic inflammatory myopathies-ILD? *

  47. According to you, for how long therapy with Nintedanib should be given in patients with Sjogren’s syndrome associated ILD?*

  48. How do you wean off a patient from antifibrotic therapy in your clinical practice in Ssc- ILD patients? *
  49. How do you wean off a patient from antifibrotic therapy in your clinical practice in RA- ILD patients? *
  50. How do you wean off a patient from antifibrotic therapy in your clinical practice in idiopathic inflammatory myopathies -ILD patients? *